<DOC>
	<DOC>NCT02182726</DOC>
	<brief_summary>The aim of the study is to investigate - the indication for MOBEC in a dose of 15 mg per day - the treatments patients were receiving before switching to 15 mg MOBEC - how treatment with 15 mg is assessed compared with previous treatment - how effective and safe treatment with 15 mg MOBEC is considered</brief_summary>
	<brief_title>Postmarketing Surveillance Study With MOBECÂ®</brief_title>
	<detailed_description />
	<mesh_term>Osteoarthritis</mesh_term>
	<mesh_term>Meloxicam</mesh_term>
	<criteria>An indication for a treatment with 15 mg MOBEC of at least four weeks the symptomatic shortterm treatment of osteoarthritis the symptomatic longterm treatment of rheumatoid arthritis (chronic polyarthritis); restriction: the recommended dose for longterm treatment of elderly patients is 7.5 mg) the symptomatic treatment of ankylosing spondylitis Treatment with MOBEC prior to the start of the study Patients with any of the general or specific contraindications of MOBEC</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2014</verification_date>
</DOC>